Madison Scientific

Madison Scientific, Inc. (MadSci™), founded in 2020, is a Chicago-based medical device company concentrated on developing solutions for individuals with hydrocephalus. The company's efforts are directed at a market where treatment options have seen minimal substantive change in nearly 75 years, presenting a significant opportunity for advancement. The business operates in the therapeutic and neuro-devices sector, serving patients and healthcare providers dealing with this incurable neurological condition that affects over a million people in the U.S.

The company's key product in development is the SmartShunt™ Hydrocephalus Management System. This implantable device is designed to offer an integrated approach to managing the condition by combining diagnostic and therapeutic functions. Its core components include a proprietary SmartValve™, a state-of-the-art intracranial pressure (ICP) sensor, and advanced algorithms. This system aims to provide personalized and informed management of hydrocephalus by monitoring ICP and using that data to optimize cerebrospinal fluid (CSF) drainage for each patient. A primary benefit of this approach is the potential to reduce the high failure rates associated with traditional shunts, which can be a significant source of stress and risk for patients.

Madison Scientific is led by CEO Dr. Tyler Wanke, a medical doctor with an MBA who is also an adjunct professor at Northwestern University's Farley Center for Entrepreneurship & Innovation. His background includes co-founding other medical spinouts, Innoblative Designs and Edge Surgical, demonstrating a track record in medical technology commercialization. The technology for the SmartShunt™ originated from the University of Wisconsin, where Dr. Wanke and his team identified an unmet physiological need and a mechanism to address it, leading to the decision to spin out the company. The business model appears to be focused on the development and eventual sale of this proprietary medical device, pending regulatory approval. The SmartShunt System is not yet authorized for sale in any country. The company has secured funding through a mix of venture capital, family offices, and non-dilutive grants from institutions like the National Institutes of Health (NIH) and the National Science Foundation (NSF), which supports its research, team growth, and product development efforts.

Keywords: hydrocephalus management, SmartShunt system, intracranial pressure sensor, cerebrospinal fluid drainage, neuro-device, medical technology, therapeutic devices, smart valve, personalized hydrocephalus management, implantable medical device, neurologic conditions, neurosurgery innovation, CSF management, WARF Ventures, Isthmus Project, Tyler Wanke, medical device funding, MedTech startup, neuro-monitoring, smart implant